[go: up one dir, main page]

BR0207151A - Moléculas de aglutinação terapêuticas - Google Patents

Moléculas de aglutinação terapêuticas

Info

Publication number
BR0207151A
BR0207151A BR0207151-7A BR0207151A BR0207151A BR 0207151 A BR0207151 A BR 0207151A BR 0207151 A BR0207151 A BR 0207151A BR 0207151 A BR0207151 A BR 0207151A
Authority
BR
Brazil
Prior art keywords
ser
asn
amino acid
thr
tyr
Prior art date
Application number
BR0207151-7A
Other languages
English (en)
Inventor
Gregorio Aversa
Frank Kolbinger
Jose M Carballido Herrera
Andras Aszodi
Jose W Saldanha
Bruce M Hall
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR0207151A publication Critical patent/BR0207151A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/289—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD45
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"MOLéCULAS DE AGLUTINAçãO TERAPêUTICAS". A invenção refere-se a uma molécula compreendendo pelo menos um sítio de aglutinação de antígeno, compreendendo na seq³ência as regiões hipervariáveis CDR1, CDR2 e CDR3, referido CDR1 tendo a seq³ência de aminoácido Asn-Tyr-lie-lie-His (NYIIH), referido CDR2 tendo a seq³ência de aminoácido Tyr-Phe-Asn-Pro-Tyr-Asn-His-Gly-Thr-Lys-Tyr-Asn-Giu-Lys-Phe-Lys- Gly (YFNPYNHGTKYNEKFKG) e referido CDR3 tendo a seq³ência de aminoácido Ser-Gly-Pro-Tyr-Ala-Trp-Phe-Asp-Thr (SGPYAWFDT); por exemplo ainda compreendendo na seq³ência as regiões hipervaráveis CDR1<39>; CDR2<39> e CDR3<39>, CDR1<39> tendo a seq³ência de aminoácido Arg-Ala-Ser-Gln-Asn-lle-Gly-Thr-Ser-lle-Gin (RASQNIGTSIQ), CDR2<39> tendo a seq³ência de aminoácido Ser-Ser-Ser-Giu-Ser-lle-Ser (SSSESIS) e CDR3<39> tendo a seq³ência de aminoácido Gln-Gln-Ser-Asn-Thr-Trp-Pro-Phe-Thr (QQSNTWPFT), por exemplo um anticorpo quimérico ou humanizado, útil como um farmacêutico.
BR0207151-7A 2001-02-12 2002-02-11 Moléculas de aglutinação terapêuticas BR0207151A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0103389.3A GB0103389D0 (en) 2001-02-12 2001-02-12 Organic compounds
PCT/EP2002/001420 WO2002072832A2 (en) 2001-02-12 2002-02-11 Therapeutic binding molecules

Publications (1)

Publication Number Publication Date
BR0207151A true BR0207151A (pt) 2004-10-05

Family

ID=9908539

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0207151-7A BR0207151A (pt) 2001-02-12 2002-02-11 Moléculas de aglutinação terapêuticas

Country Status (26)

Country Link
US (1) US20040096901A1 (pt)
EP (1) EP1421191B1 (pt)
JP (2) JP2004533816A (pt)
KR (1) KR100752029B1 (pt)
CN (1) CN100529074C (pt)
AR (1) AR035539A1 (pt)
AT (1) ATE526409T1 (pt)
BR (1) BR0207151A (pt)
CA (1) CA2437963A1 (pt)
CZ (1) CZ20032129A3 (pt)
EC (1) ECSP034714A (pt)
ES (1) ES2374554T3 (pt)
GB (1) GB0103389D0 (pt)
HK (1) HK1071769A1 (pt)
HU (1) HUP0401560A3 (pt)
IL (1) IL157136A0 (pt)
MX (1) MXPA03007197A (pt)
NO (1) NO20033549L (pt)
NZ (1) NZ548865A (pt)
PE (1) PE20020871A1 (pt)
PL (1) PL369516A1 (pt)
RU (2) RU2328506C2 (pt)
SK (1) SK10082003A3 (pt)
TW (1) TWI332524B (pt)
WO (1) WO2002072832A2 (pt)
ZA (1) ZA200305911B (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050069538A1 (en) 2003-09-18 2005-03-31 Gregorio Aversa Therapeutic binding molecules
US7460960B2 (en) * 2002-05-10 2008-12-02 Epitome Biosystems, Inc. Proteome epitope tags and methods of use thereof in protein modification analysis
US7618788B2 (en) * 2002-05-10 2009-11-17 Millipore Corporation Proteome epitope tags and methods of use thereof in protein modification analysis
DE602004026081D1 (de) * 2003-09-18 2010-04-29 Novartis Ag Therapeutische humanisierte antikörper gegen cd45-isoformen
WO2006081620A1 (en) 2005-02-02 2006-08-10 Newsouth Innovations Pty Limited Cd4+ cd25+ t-cells activated to a specific antigen
FR2892724B1 (fr) * 2005-11-02 2008-01-04 Lab Francais Du Fractionnement Anticorps cytotoxiques diriges contre des anticorps inhibiteurs du facteur viii.
US7855057B2 (en) * 2006-03-23 2010-12-21 Millipore Corporation Protein splice variant/isoform discrimination and quantitative measurements thereof
US8569059B2 (en) 2006-08-02 2013-10-29 Newsouth Innovations Pty Limited Method of identifying CD4+ CD25+ T-cells activated to an antigen which express CD8
AU2008258646A1 (en) * 2007-06-05 2008-12-11 Fondazione Centro San Raffaele Del Monte Tabor Induction of tolerogenic phenotype in mature dendritic cells
JP2013507919A (ja) * 2009-10-16 2013-03-07 ダウ アグロサイエンシィズ エルエルシー 植物細胞に生体分子を送達するためのデンドリマーナノテクノロジーの使用
US8962804B2 (en) 2010-10-08 2015-02-24 City Of Hope Meditopes and meditope-binding antibodies and uses thereof
EP2502631A1 (en) 2011-03-22 2012-09-26 Medizinische Hochschule Hannover Immune suppressor and its use
US9428553B2 (en) 2012-02-10 2016-08-30 City Of Hope Meditopes and meditope-binding antibodies and uses thereof
GB201409558D0 (en) 2014-05-29 2014-07-16 Ucb Biopharma Sprl Method
GB201412659D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
EP3026060A1 (en) * 2014-11-26 2016-06-01 Miltenyi Biotec GmbH Humanized antibody or fragment thereof specific for CD45R0
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
GB201601075D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
GB201521389D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Method
GB201521383D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl And Ucb Celltech Method
GB201521391D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521393D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521382D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
EP3630836A1 (en) 2017-05-31 2020-04-08 Elstar Therapeutics, Inc. Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
IL301859A (en) 2020-10-15 2023-06-01 UCB Biopharma SRL Binding molecules that multimerise cd45

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6106834A (en) * 1993-06-02 2000-08-22 Research Corporation Technologies, Inc. Use of anti-CD45 leukocyte antigen antibodies for immunomodulation
JPH08510922A (ja) * 1994-03-17 1996-11-19 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 抗ＥＧＦＲ一本鎖Ｆｖおよび抗ＥＧＦＲ抗体
JPH09191886A (ja) * 1996-01-19 1997-07-29 Asahi Breweries Ltd ヒト高親和性ＩｇＥ受容体に対するヒト型化抗体、半キメラ抗体およびキメラ抗体

Also Published As

Publication number Publication date
EP1421191B1 (en) 2011-09-28
NZ548865A (en) 2008-03-28
JP2004533816A (ja) 2004-11-11
MXPA03007197A (es) 2003-12-04
KR100752029B1 (ko) 2007-08-28
WO2002072832A2 (en) 2002-09-19
CN1551919A (zh) 2004-12-01
ES2374554T3 (es) 2012-02-17
PE20020871A1 (es) 2002-11-11
GB0103389D0 (en) 2001-03-28
HUP0401560A3 (en) 2012-09-28
CN100529074C (zh) 2009-08-19
US20040096901A1 (en) 2004-05-20
KR20040036684A (ko) 2004-04-30
NO20033549D0 (no) 2003-08-11
CZ20032129A3 (cs) 2003-11-12
NO20033549L (no) 2003-10-10
ECSP034714A (es) 2003-09-24
AR035539A1 (es) 2004-06-02
ATE526409T1 (de) 2011-10-15
RU2405790C2 (ru) 2010-12-10
PL369516A1 (en) 2005-04-18
TWI332524B (en) 2010-11-01
WO2002072832A3 (en) 2004-03-25
RU2328506C2 (ru) 2008-07-10
JP2009034108A (ja) 2009-02-19
RU2008100239A (ru) 2009-07-20
HK1071769A1 (en) 2005-07-29
ZA200305911B (en) 2004-06-28
EP1421191A2 (en) 2004-05-26
CA2437963A1 (en) 2002-09-19
SK10082003A3 (sk) 2004-03-02
IL157136A0 (en) 2004-02-08
RU2003126168A (ru) 2005-03-10
HUP0401560A2 (hu) 2004-11-29

Similar Documents

Publication Publication Date Title
BR0207151A (pt) Moléculas de aglutinação terapêuticas
ECSP066432A (es) Moléculas de enlace terapéuticas
AR035581A1 (es) Anticuerpos para il-1beta humana
HRP20181069T1 (hr) Antagonistička protutijela na il-17
HRP20020693B1 (en) HUMANIZED ANTIBODIES THAT SEQUESTER AMYLOID Abeta PEPTIDE
AR046379A1 (es) Una molecula de enlace de mcp-1 humana, un proceso para dicha produccion, construcciones de adn, un vector de expresion, composiciones farmaceuticas y el uso de dicha molecula de enlace de mcp-1 para la preparacion de un medicamento
CO5280086A1 (es) Molecula de enlace de cd154, construccion de adn, vector de expresion, composcion y combinacion farmaceutica
PE20011219A1 (es) ANTICUERPOS PARA IL-1ß HUMANA
RS51468B (en) COMPLETE HUMAN ANTIBODIES FOR HUMANS 4-1BB (CD137)
RS52889B (sr) Terapijsko humano anti-il-1r1 monoklonsko antitelo
PL406852A1 (pl) Preparat zawierający ludzkie przeciwciała do leczenia zaburzeń związanych z TNF-α
DK3483183T3 (da) Immunokonjugat omfattende humaniserede rs7-antistoffer
GEP20074222B (en) Antibodies to cd40
PE20050925A1 (es) Anticuerpo recombinante humanizado anti-interleuquina 10
BRPI0410338A (pt) composição farmacêutica compreendendo um constructo de anticorpo biespecìfico para epcam, processo para sua produção, uso de um constructo biespecìfico, kit contendo o mesmo e método para a prevenção, tratamento ou alìvio de uma doença tumoral
EP2796466A3 (en) Humanized antibody molecules specific for IL-31
CY1110700T1 (el) Ανασυνδυασμενα αντισωματα αντι-cd30 και χρησεις αυτων
RS51829B (sr) Ljudska antitela specifična za interleukin 15 (il-15)
CU23292B7 (es) Anticuerpos monoclonales humanos de ctla-4
BR0318454A (pt) anticorpos dirigidos a hormÈnio da paratireóide (pth) e seus usos
BR0109549A (pt) Utilização de moléculas que se ligam a cd25 no tratamento de doenças inflamatórias do trato gastrointestinal
KR940006602A (ko) 면역글로불린 이소타입에 대한 재조형 모노클로날 항체
CY1107785T1 (el) Χρηση του βασιλιξιμαμπ στη θεραπεια της ρευματοειδους αρθριτιδας ´η νοσων του δερματος
TH53886A (th) แอนติบอดี้ต่อ il-1b ในมนุษย์
UA84539C2 (ru) Человеческое моноклональное антитело, которое специфически связывается с cd40, фармацевтическая композиция, которая его содержит, и применение антитела для производства лекарственного средства для лечения cd 40-отрицательной опухоли у человека

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2206 DE 16/04/2013.